Regenicin, Inc. reported earnings results for the full year ended September 30, 2022. For the full year, the company reported net loss was USD 0.639262 million compared to USD 0.670602 million a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | +9,900.00% |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 15.35K | |
+8.95% | 115B | |
+11.43% | 106B | |
-2.27% | 21.96B | |
-14.44% | 21.87B | |
-5.29% | 19.21B | |
-4.19% | 18.08B | |
-38.29% | 17.71B | |
+7.49% | 14.32B | |
+35.91% | 12.42B |
- Stock Market
- Equities
- RGIN Stock
- News Regenicin, Inc.
- Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022